Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

 – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 –

 – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 –